Posts

Pharma IP & Regulatory Update 2026: Paragraph IV Filings, China RDP, and Case Law: Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc

Image
1. Recent USFDA Paragraph IV Filings (May 2026 Update) The USFDA’s Paragraph IV database was recently updated to track key Abbreviated New Drug Applications (ANDAs) .  Broadly, four major drugs and their developers seek lucrative  180-day market exclusivity . Key Drug Breakdown & Technical Challenges Letermovir (Prevymis – Merck) Indication: Prophylaxis of cytomegalovirus (CMV) infection in bone marrow and kidney transplant recipients . Market Dynamics: Nearing the $1 billion mark in annual US revenue . There is currently only one generic filer with a substantially complete ANDA . Technical/IP Barriers: Letermovir is a highly complex zwitterionic compound . Generic applicants must circumvent US Patent No. 10,603,384 , which governs solubility and stable formulations for intravenous administration . Currently, only Honour Labs has filed a Drug Master File (DMF) . Abemaciclib (Verzenio – Eli Lilly) Indication: HR+, HER2-negative advanced or metastatic breas...
Read more

2026 Biopharma News: Filkri Approval, Langlara Interchangeability, and CDSCO ONDLS Mandate

Image
Biopharma Industry Insights 2026: New Biosimilar Approvals & Key IP Rulings The biopharmaceutical landscape continues to evolve rapidly in 2026 with critical regulatory updates, market entries, and high-stakes intellectual property decisions. In this post, we break down the most significant developments from the latest industry updates, including two major USFDA biosimilar clearances, crucial export compliance changes in India, and a landmark European Patent Office (EPO) ruling. 1. USFDA Expands Oncology Supportive Care with Filkri Approval The USFDA has officially expanded the oncology landscape by approving Filkri (filgrastim-laha) . Developed by Accord BioPharma (the U.S. speciality division of India-based Intas Pharmaceuticals ), Filkri serves as a biosimilar referencing Amgen’s blockbuster drug, Neupogen . Key Details & Market Impact: Indications: It is a short-acting granulocyte colony-stimulating factor (G-CSF) designed to stimulate neutrophil production and combat s...
Location: Mumbai, Maharashtra, India
Read more